Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Secretary General João Goncalves of the Portuguese Trade Association for Medical Devices Companies (APORMED) – Portugal’s medtech association – welcomes readers to explore relevant trades in the medical devices segment.…
Nelson Pires provides an insightful update on Portugual’s pharmaceutical market evolution as well as Jaba Recordati’s ambitious Portuguese affiliate. Pires shares that diversification is one technique of navigating the market,…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Medicinalia Cormedica is the leading Portuguese distributor of medical devices. Antonio Cabral, who has led the business in Portugal for almost a decade, introduces the company, explains its business model…
Carla Benedito, general manager of Shire Portugal, provides useful insight into the rare diseases landscape in Portugal. Carla discusses market access models for innovative and rare treatments, encouraging dialogue between…
Olga Insua, the new American general manager for Novo Nordisk Portugal, fresh off the plane from Spain, provides an exclusive insight into her impressive career at the company, the blending…
Antonio Leão discusses Lilly Portugal’s sustained growth record in recent years, its ambition to introduce two new innovative treatments to the market every year until 2022, and their empowering approach…
Salvador Fernandes, Ralph Steffen and Sofia Fernandes, chairman, production manager, and marketing manager respectively, discuss Sidefarma’s positioning in the Portuguese manufacturing landscape, and the strong relationship evolving between the government…
Antonio Portela, seven years into leading the Bial operation in Portugal, shares his views on internationalization and how to maintain a stable company culture when approaching new and diverse markets.…
Cristina Campos is well known on the Portuguese pharmaceutical circuit, directing the affiliate of market leader, Novartis, and holding a position as vice-president at APIFARMA, the Portuguese Pharmaceutical Association. In…
Filipe Assoreira and José Albuquerque, president and secretary general respectively of P-Bio – Portugal’s bioindustry association – discuss the importance of innovation to the biopharmaceutical industry and the importance of…
Paulo Teixeira shines a light on Pfizer’s promising pipeline for 2018, the market access environment in Portugal and the clinical trial landscape. Teixeira intends to contribute to improving society’s perception…
See our Cookie Privacy Policy Here
